410 related articles for article (PubMed ID: 26565813)
1. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway.
Wang T; Seah S; Loh X; Chan CW; Hartman M; Goh BC; Lee SC
Oncotarget; 2016 Jan; 7(3):2532-44. PubMed ID: 26565813
[TBL] [Abstract][Full Text] [Related]
2. Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.
Yanai A; Inoue N; Yagi T; Nishimukai A; Miyagawa Y; Murase K; Imamura M; Enomoto Y; Takatsuka Y; Watanabe T; Hirota S; Sasa M; Katagiri T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):197-203. PubMed ID: 25600244
[TBL] [Abstract][Full Text] [Related]
3. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.
Hu C; Huang L; Gest C; Xi X; Janin A; Soria C; Li H; Lu H
J Hematol Oncol; 2012 Jul; 5():16. PubMed ID: 22534171
[TBL] [Abstract][Full Text] [Related]
4. HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway.
Qi XF; Zheng L; Lee KJ; Kim DH; Kim CS; Cai DQ; Wu Z; Qin JW; Yu YH; Kim SK
Cell Death Dis; 2013 Feb; 4(2):e518. PubMed ID: 23449454
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
6. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
[TBL] [Abstract][Full Text] [Related]
7. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
Saini KS; Loi S; de Azambuja E; Metzger-Filho O; Saini ML; Ignatiadis M; Dancey JE; Piccart-Gebhart MJ
Cancer Treat Rev; 2013 Dec; 39(8):935-46. PubMed ID: 23643661
[TBL] [Abstract][Full Text] [Related]
8. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
[TBL] [Abstract][Full Text] [Related]
9. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
10. Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma.
Milosevic Z; Pesic M; Stankovic T; Dinic J; Milovanovic Z; Stojsic J; Dzodic R; Tanic N; Bankovic J
Transl Res; 2014 Nov; 164(5):411-23. PubMed ID: 25016932
[TBL] [Abstract][Full Text] [Related]
11. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors.
Dworakowska D; Wlodek E; Leontiou CA; Igreja S; Cakir M; Teng M; Prodromou N; Góth MI; Grozinsky-Glasberg S; Gueorguiev M; Kola B; Korbonits M; Grossman AB
Endocr Relat Cancer; 2009 Dec; 16(4):1329-38. PubMed ID: 19620247
[TBL] [Abstract][Full Text] [Related]
12. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
[TBL] [Abstract][Full Text] [Related]
13. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
14. Jolkinolide B induces apoptosis in MCF-7 cells through inhibition of the PI3K/Akt/mTOR signaling pathway.
Xu HY; Chen ZW; Hou JC; Du FX; Liu JC
Oncol Rep; 2013 Jan; 29(1):212-8. PubMed ID: 23129237
[TBL] [Abstract][Full Text] [Related]
15. Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression.
Polo ML; Riggio M; May M; Rodríguez MJ; Perrone MC; Stallings-Mann M; Kaen D; Frost M; Goetz M; Boughey J; Lanari C; Radisky D; Novaro V
Oncotarget; 2015 Sep; 6(26):22081-97. PubMed ID: 26098779
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
17. [Correlation of p38 mitogen-activated protein kinase signal transduction pathway to uPA expression in breast cancer].
Han YC; Zeng XX; Wang R; Zhao Y; Li BL; Song M
Ai Zheng; 2007 Jan; 26(1):48-53. PubMed ID: 17222367
[TBL] [Abstract][Full Text] [Related]
18. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
19. Thymosin alpha 1 suppresses proliferation and induces apoptosis in breast cancer cells through PTEN-mediated inhibition of PI3K/Akt/mTOR signaling pathway.
Guo Y; Chang H; Li J; Xu XY; Shen L; Yu ZB; Liu WC
Apoptosis; 2015 Aug; 20(8):1109-21. PubMed ID: 26002438
[TBL] [Abstract][Full Text] [Related]
20. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
